Analysis of the performances of the Covid-19 therapeutic approaches in the United Arab Emirates

Objectives: To evaluate the performances of the therapeutic approaches adopted in the United Arab Emirates to fight Covid-19 infection.

Methods: Statistical analysis of the number of cases and fatalities for the United Arab Emirates. The fatality rates are compared to those of reference countries adopting different approaches.

Results: The United Arab Emirates outperformed the reference countries with a much smaller number of fatalities. While this number is not only driven by therapies, the different therapeutic approaches are the most important driver.

Conclusions: Combination therapies are most effective than single drug therapies. The use of antivirals especially in the early stages reduces the number of fatalities.

Covid-19; Antivirals; Combination therapies

[1] Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. Journal of Clinical Investigation. 2020; 130: 5235-5244.

[2] Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. International Journal of Infectious Diseases. 2020; 94: 68-71.

[3] Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020; 38: 661- 671. e2.

[4] doh.gov.ae/-/media/7BD7B077D8F846B48A70C5872902DD1C.ashx

[5] Kumar R, Sharma A, Srivastava JK, Siddiqui MH, Uddin MS, Aleya L. Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. Environmental Science and Pollution Research. 2021; 1-14.

[6] Kumar R, Srivastava JK, Singh R, Siddiqui MH, Mansouri RA, Abdulhakim JA, et al. Available Compounds with Therapeutic Potential against COVID-19: antimicrobial therapies, supportive care and probable vaccines. Frontiers in pharmacology. 2020; 11: 1592.

[7] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Journal of the American Medical Association. 2020; 323: 1824-1836.

[8] Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosup-pressed states: a clinical-therapeutic staging proposal. The Journal of Heart and Lung Transplantation. 2020; 39: 405-407.

[9] Boretti A. Favipiravir use for SARS CoV-2 infection. Pharmacological Reports. 2020; 72: 1542-1552.

[10] Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: an open-label control study. Engineering. 2020; 6: 1192-1198.

[11] Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, et al. Clinical Outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. European Journal of Pharmaceutical Sciences. 2021; 157: 105631.

[12] Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Critical Care. 2020; 24: 413.

[13] Breining P, Frølund AL, Højen JF, Gunst JD, Staerke NB, Saedder E, et al. Camostat mesylate against SARS-CoV-2 and COVID-19-rationale, dosing and safety. Basic & Clinical Pharmacology & Toxicology. 2021; 128: 204-212.

[14] Hofmann-Winkler H, Moerer O, Alt-Epping S, Bräuer A, Büttner B, Müller M, et al. Camostat mesylate may reduce severity of coronavirus disease 2019 sepsis: a first observation. Critical Care Explorations. 2020; 2: e0284.

[15] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. New England Journal of Medicine. 2020; 382: 1787-1799.

[16] Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean Medical Science. 2020; 35: e79.

[17] Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2020; 396: 1345-1352.

[18] Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. Journal of Medical Virology. 2020; 92: 740-746.

[19] Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. International Journal of Antimicrobial Agents. 2020; 56: 106114.

[20] Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. Journal of Antimicrobial Chemotherapy. 2020; 75: 3366-3372.

[21] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19-final report. New England Journal of Medicine. 2020; 383: 1813-1826.

[22] Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Medicine and Infectious Disease. 2020; 34: 101615.

[23] McCreary EK, Angus DC. Efficacy of remdesivir in COVID-19. Journal of the American Medical Association. 2020; 324: 1041-1042.

[24] Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? The Lancet Rheumatology. 2020; 2: e428-e436.

[25] Ellison-Hughes GM, Colley L, O’Brien KA, Roberts KA, Agbaedeng TA, Ross MD. The role of MSC therapy in attenuating the damaging effects of the cytokine storm induced by COVID-19 on the heart and cardiovascular system. Frontiers in cardiovascular medicine. 2020; 7: 602183.

[26] Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. Journal of the American Medical Association. 2020; 324: 131-132.

[27] Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatology. 2020; 2: 276-282.

[28] Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatology. 2020; 2: 276-282.

[29] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020; 117: 10970-10975.

[30] Zhou Q, Wei XS, Xiang X, Wang X, Wang ZH, Chen V, et al. Interferon-α2b treatment for COVID-19. 2020; MedRxiv.

[31] Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology. 2020; 146: 137-146.e3.

[32] Lee JS, Shin E. The type I interferon response in COVID-19: implications for treatment. Nature Reviews Immunology. 2020; 20: 585-586.

[33] Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-α2b treatment for COVID-19. Frontiers in Immunology. 2020; 11: 1061.

[34] Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrobial Agents and Chemotherapy. 2020; 64: e01061-20.

[35] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. Journal of the American College of Cardiology. 2020; 75: 2950-2973.

[36] Chaudhary R, Kreutz RP, Bliden KP, Tantry US, Gurbel PA. Personal-izing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry. Thrombosis and Haemostasis. 2020; 120: 1594-1596.

[37] Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020; 12: 100190.

[38] Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? Medicine in Drug Discovery. 2020; 5: 100028.

[39] Cereda E, Bogliolo L, de Stefano L, Caccialanza R. A brief discussion of the benefit and mechanism of vitamin D supplementation on coronavirus disease 2019. Current Opinion in Clinical Nutrition & Metabolic Care. 2021; 24: 102-107.

[40] Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Network Open. 2020; 3: e2019722.

[41] Anuk AT, Polat N, Akdas S, Erol SA, Tanacan A, Biriken D, et al. The relation between trace element status (zinc, copper, magnesium) and clinical outcomes in COVID-19 infection during pregnancy. Biological trace element research. 2020; 1-10.

[42] Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. Frontiers in Immunology. 2020; 11: 1712.

[43] HCQ for COVID-19. Available at: c19study.com/.

[44] Procter BC, Ross C, Pickard V, Smith E, Hanson C, McCullough PA. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine. 2020; 21: 611-614.

[45] Su Y, Ling Y, Ma Y, Tao L, Miao Q, Shi Q, et al. Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. BioScience Trends. 2020; 14: 408-414.

[46] Sogut O, Can MM, Guven R, Kaplan O, Ergenc H, Umit TB, et al. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: a pilot observational study. The American Journal of Emergency Medicine. 2021; 40: 41-46.

[47] Agusti A, Guillen E, Ayora A, Anton A, Aguilera C, Vidal X, et al. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial. Enfermedades Infecciosas Y Microbiología ClíNica. 2020; S0213-005X(20)30413-4.

[48] Omrani AS, Pathan SA, Thomas SA, Harris TRE, Coyle PV, Thomas CE, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe COVID-19. EClinicalMedicine. 2020; 29-30: 100645.

[49] Szente Fonseca SN, de Queiroz Sousa A, Wolkoff AG, Moreira MS, Pinto BC, Valente Takeda CF, et al. Risk of hospitalization for COVID-19 outpatients treated with various drug regimens in Brazil: comparative analysis. Travel Medicine and Infectious Disease. 2020; 38: 101906.

[50] Derwand R, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. International Journal of Antimicrobial Agents. 2020; 56: 106214.

[51] Prodromos C, Rumschlag T. Hydroxychloroquine is effective, and consistently so used early, for COVID-19: a systematic review. New microbes and new infections. 2020; 38: 100776.

[52] Hong KS, Jang JG, Hur J, Lee JH, Kim HN, Lee W, et al. Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication. Infection & Chemotherapy. 2020; 52: 396.

[53] RECOVERY. Randomised evaluation of COVID-19 therapy. 2020. Available at: www.recoverytrial.net/files/protocol-archive/recovery-protocol-v4-0-2020-04-14.pdf (Accessed: 30 January 2021).

[54] WHO Solidarity Trial Consortium, 2020. Repurposed antiviral drugs for COVID-19-interim WHO SOLIDARITY trial results. New England Journal of Medicine. 2021; 384:497-511.

[55] RT question more. Thousands of Israelis test POSITIVE for Covid-19 despite receiving Pfizer/BioNTech jab. 2021. Available at: www.rt.com/news/513139-israel-pfizer-vaccine-coronavirus/ (Accessed: 30 January 2021).

[56] Efrati I, Linder R. Thousands of Israelis tested positive for coronavirus after first vaccine shot. Available at: www.haaretz.com/israel-news/thousands-of-israelis-tested-positive-for-coronavirus-after-first-vaccine-shot-1.9462478.